24 Papers
203 Citations
Nancy Tait is an academic researcher from University of Maryland Marlene and Stewart Greenebaum Cancer Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 10, co-authored 17 publications. Previous affiliations of Nancy Tait include University of Maryland, Baltimore.
Chat about Author
Papers
•Journal Article
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Barbara A. Conley,Merrill J. Egorin,Nancy Tait,D M Rosen,Edward A. Sausville,G Dover,R J Fram,D. A. Van Echo +7 more
TL;DR: Because peak plasma concentrations near those effective in vitro (0.5-1 mM) were achieved, but butyrate disappeared from plasma by 5 h after dose, this work is pursuing dose escalation with dosing three times daily, beginning at a dose of 450 mg/kg/day.
158
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Martin J. Edelman,Kenneth S. Bauer,Kenneth S. Bauer,Shyam L. Khanwani,Nancy Tait,Jane B. Trepel,Judith E. Karp,Noble N. Nemieboka,Eun Joo Chung,David A. Van Echo +9 more
TL;DR: Tributyrin is well tolerated and levels associated with in vitro activity are achieved with three times daily dosing with patients with advanced solid tumors without evidence of progression.
93
Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy
TL;DR: It remains uncertain whether the MIs were a byproduct of the capillary leak syndrome in patients with underlying coronary artery disease or whether rIL-2 directly or indirectly damages cardiac muscle.
79
Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics
B. A. Conley,Merrill J. Egorin,Rajeshwari Sridhara,Rebecca S. Finley,Ramzi K. Hemady,Suhlan Wu,Nancy Tait,David A. Van Echo +7 more
TL;DR: Although not statistically significant, more frequent and severe toxicity tended to occur in patients with higher plasma peak ATRA concentrations, and the recommended once-daily ATRA dose is 215 mg/m2, although significant interpatient variability is observed in toxicity and plasma retinoid concentrations.
77
Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects
Katherine Rak Tkaczuk,Binbin Yue,Min Zhan,Nancy Tait,Lavanya Yarlagadda,Huifang Dai,Ginette Serrero +6 more
- 12 Jul 2011
TL;DR: The data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.
48